Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

Launched by MANSOURA UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether taking probiotic supplements can help slow down the progression of chronic kidney disease (CKD) in patients who have moderate to severe forms of the condition. Probiotics are beneficial bacteria that can improve gut health, and researchers want to see if they can also improve kidney function, lower inflammation, and reduce harmful substances in the body. The study will also check if probiotics are safe for CKD patients.

To participate, you need to be an adult aged 18 or older with CKD Stage III or IV. Participants will be randomly assigned to either receive the probiotic or a placebo (a dummy treatment) for six months, with regular visits for checkups and tests to monitor kidney health and any side effects. Important criteria for joining include not currently taking probiotics, being in stable health, and not having serious gastrointestinal diseases or cancer. This study is not yet recruiting, but it aims to provide valuable insights into how probiotics might help people with chronic kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged ≥ 18 years (both males and females).
• • Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by eGFR.
• • Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.
• • Not currently on probiotic supplementation or prebiotic therapy.
• • Willing to provide informed consent and comply with the study protocol, including clinic visits and sample collection.
• Exclusion Criteria:
• • CKD Stage I, II, or V, or on dialysis.
• • Currently using probiotics or prebiotics as part of their diet or treatment.
• • History of active malignancy (cancer) or undergoing chemotherapy.
• • Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).
• • Pregnant or breastfeeding women (due to safety concerns).
• • Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis).
• • Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.
• • Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.